The Pharmacy and Poisons Board has approved the use of a prescription drug for the treatment of prostate cancer.
The drug, ZYTIGA (abiraterone acetate), is manufactured by Janssen, one of the pharmaceutical companies of Johnson & Johnson.
The local pharmacy regulator has approved the use of the once-daily medication for the treatment of metastatic castration-resistant prostate cancer ahead of a chemotherapy regime.
“The drug is only licensed for the treatment of advanced prostate cancer cases post-chemotherapy,” Janssen Kenya Country Manager Marseille Onyango said.
